Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: INTRODUCTION: This study investigated the efficacy and safety of teneligliptin as an add-on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. MATERIALS AND METHODS: In this multicenter, double-blind, randomized, placebo-controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0-10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily (n = 116) or placebo (n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters. RESULTS: At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least-squares mean difference -0.69%; 95% confidence interval -0.83 to -0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment-emergent adverse events between the groups. DISCUSSION: The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.
DOI: 10.1111/jdi.70491
Authors: Soo Heon Kwak, KyungWan Min, Bon Jeong Ku, Ji A Seo, Sang Yong Kim, Sang Youl Rhee, Gyuri Kim, Jae Hyoung Cho, Sang‐Ah Chang, Sung Hee Choi, Seung Jin Han, Jeong Hyun Park, Kyu Jeung Ahn, Chul Woo Ahn, Bong‐Soo Cha, Hye Soon Kim, Joo Young Nam, Heung Yong Jin, Hyuk‐Sang Kwon, Sin Gon Kim, Sang Soo Kim, Jun Sung Moon, Kang Seo Park, BokJin Hyun, SunYoung Kim, Kyong Soo Park
Institutions: Seoul National University, Seoul National University Hospital, Eulji University Nowon Eulji Medical Center, Chungnam National University, Chungnam National University Hospital, Korea University, Korea University Ansan Hospital, Chosun University, Chosun University Hospital, Kyung Hee University, Kyung Hee University Medical Center, Samsung Medical Center, Sungkyunkwan University, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, The Catholic University of Korea Eunpyeong St. Mary's Hospital, Seoul National University Bundang Hospital, Ajou University, Inje University, Inje University Busan Paik Hospital, Kyung Hee University Hospital at Gangdong, Yonsei University, Gangnam Severance Hospital, Yonsei University Health System, Keimyung University Dongsan Hospital, Keimyung University, National Health Insurance Service Ilsan Hospital, Jeonbuk National University Hospital, Jeonbuk National University, The Catholic University of Korea Yeouido St. Mary's Hospital, Korea University Anam Hospital, Pusan National University Hospital, Yeungnam University Medical Center, Yeungnam University College, Yeungnam University, Daejeon Eulji Medical Center, Eulji University, Handok (South Korea), Konkuk University, Konkuk University Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,850
OpenAlex ID: W7230234812
